|Year : 2014 | Volume
| Issue : 3 | Page : 135-139
175Yb-TTHMP as a good candidate for bone pain palliation and substitute of other radiopharmaceuticals
Department of Radiation Application Engineering, Shahid Beheshti University, Tehran, Iran
|Date of Web Publication||11-Jul-2014|
Department of Radiation Application Engineering, Shahid Beheshti University, Tehran, 19839 - 63113
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Bone metastasis is one of the most frequent causes of pain in cancer patients. Different radioisotopes such as P-32, Sm-153, Ho-166, Lu-177, and Re-186 with several chemical ligands as ethylenediaminetetramethylene phosphonic acid (EDTMP), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid (DOTMP), and propylenediaminetetramethylene phosphonate (PDTMP) are recommended for bone pain palliation. In this work, 175 Yb-triethylenetetraminehexamethylene phosphonic acid (TTHMP) was produced as a proper alternative to other radiopharmaceuticals. Relatively long half-life (T 1/2 = 4.18 days), maximum energy beta particle Eβ =470 keV (86.5%), low abundance gamma emission 396 keV (6.4%), 286 keV (3.01%), 113.8 keV (1.88%) and low cost are considered advantageous of Yb-175 are to wider usage of this isotope; in addition, TTHMP is an ideal carrier moiety for bone metastases. Production, quality control, and biodistribution studies of 175 Yb-TTHMP were targeted. Yb-175 chloride was obtained by thermal neutron bombardment of a natural Yb 2 O 3 sample at Tehran Research Reactor (TRR), radiolabeling was completed in 1 h by the addition of TTHMP at the room temperature and pH was 7.5-8, radiochemical purity was higher than 95%. Biodistribution studies in normal rats were carried out. The results showed favorable biodistribution features of 175 Yb-TTHMP, indicating significant accumulation in bone tissues compared with clinically used bone-seeking radiopharmaceuticals. This research presents 175 Yb-TTHMP can be a good candidate for bone pain palliation and substitute of other radiopharmaceuticals, however, further biological studies in other mammals are still needed.
Keywords: Biodistribution, bone metastases, radiopharmaceutical, TTHMP, Ytterbium-175
|How to cite this article:|
Safarzadeh L. 175Yb-TTHMP as a good candidate for bone pain palliation and substitute of other radiopharmaceuticals. Indian J Nucl Med 2014;29:135-9
|How to cite this URL:|
Safarzadeh L. 175Yb-TTHMP as a good candidate for bone pain palliation and substitute of other radiopharmaceuticals. Indian J Nucl Med [serial online] 2014 [cited 2022 May 26];29:135-9. Available from: https://www.ijnm.in/text.asp?2014/29/3/135/136555
| Introduction|| |
Bone metastases are particularly common in patients with breast, prostate, and lung cancer.  In 80% of the cases, bone metastases are located in several sites and can produce some complications, such as pathologic fracture, mainly femur and humerus; hypercalcemia (10% of cases); and spinal cord compression (5% of cases).  Compared to the other conventional methods, such as use of analgesics and external beam radiotherapy, systematic palliative therapy using suitable bone-seeking radiopharmaceuticals have emerged as the most efficacious treatment modality for patients with multiple skeletal lesions. , The major challenge in developing effective radiopharmaceuticals for palliative treatment of bone pain due to skeletal metastasis is to deliver adequate dose of ionizing radiation at the skeletal lesion sites with minimum radiation-induced bone marrow suppression.  Radioactive isotopes of phosphorus ( 32 P) and strontium ( 89 Sr) were the first radiopharmaceuticals used for treatment of skeletal metastases in patients. , Other beta-emitting radionuclides such as 186 Re, 153 Sm, 177 Lu, 117m Sn, 166 Ho, and 175 Yb are recommended for this purpose. ,,,,,, All agents have benefits and risks. The agents differ in terms of efficacy, duration of pain palliation, tumoricidal effects, ability to repeat treatments, toxicity, and other aspects. 
Ytterbium-175 is one of radioisotopes that can be used for bone pain palliation. The thermal neutron cross-section of 174 Yb is 63.2 barns.  Therefore, it is possible to produce 175 Yb in adequate specific activity using medium flux reactors. It decays by emission of beta particles 470 keV maximum energy (86.5%) to stable 175 Lu. The prominent gamma-rays emitted from 175 Yb are 113.8 keV (1.88%), 286 keV (3.01%), and 396 keV (6.4%); these energies are suitable for imaging studies and low dose delivering for the patients.  Also, the physical half-life of 175 Yb is relatively longer (compared to 153 Sm or 166 Ho) and provide logistic advantages for facilitating supply to nuclear medicine centers far away from the reactors.
Multidentate polyaminopolyphosphonic acid ligands are known to form stable chelates with many metals including lanthanides. Among them, triethylenetetraminehexamethylene phosphonic acid (TTHMP) can be envisaged as an ideal carrier moiety, for the development of beta emitter-based radiopharmaceuticals, for bone palliation.  In this research; preparation, quality control, and biodistribution study of 175 Yb-TTHMP complex in animal model has been carried out.
| Materials and methods|| |
Natural ytterbium oxide was purchased from Isotec Inc, USA. All chemical components were obtained from Sigma-Aldrich Chemical Co. UK. All radioactivities counting related to paper chromatography were carried out by using a NaI (Tl) scintillation counter on adjustment of the baseline at 396 keV. The activity as well as the radionuclidic purity of the 175 Yb produced was ascertained by gamma spectroscopy on the base of 396 keV peak by using the high-purity germanium (HPGe) detector and beta-spectroscopy was carried out by the Wallac 1220 Quantulus liquid scintillation spectrometer. Animal studies were performed in accordance with the United Kingdom Biological Council's Guidelines on the Use of Living Animals in Scientific Investigations. All the values were expressed as mean ± standard deviation (mean ± SD).
Production and quality control of 175 YbCl 3
175Yb was produced by thermal neutron bombardment of natural Yb 2 O 3 target with isotopic purity of 31.8% for 174 Yb at Tehran Research Reactor (TRR) with neutron flux of 3 × 10 13 n/cm 2 /s by production scheme; 174 Yb (n, γ) 175 Yb → 175 Lu (stable). A weighed amount of Yb 2 O 3 powder was flame sealed into a quartz ampule under vacuum and cold welded into aluminum can. Irradiation was carried out for 7 days. Irradiated Yb 2 O 3 powder was dissolved in 1 ml of 0.1 M HCl by gentle warming. The resultant solution was evaporated to near dryness and reconstituted in 1 ml of double-distilled water. For radionuclidic purity determination, the samples were checked by gamma-ray spectroscopy on an HPGe detector. The radiochemical purity of 175 YbCl 3 was checked using Whatman no. 3 chromatography paper (was obtained from Maidstone, UK) in NH 4 OH:MeOH:H 2 O (1:10:20) system.
Synthesis of TTHMP
The experimental procedure for the synthesis of TTHMP ligand was in accordance with other bisphosphonates as reported. For synthesis of TTHMP, a quantity of 0.48 g (3.3 mmol) of triethylenetetramine was dissolved in 0.75 mL of concentrated HCl and a concentrated aqueous solution of 1.62 g (20 mmol) of phosphorous acid. The resulting solution was heated to reflux temperature and 3.2 mL of 37% aqueous formaldehyde solution (40 mmol) was added dropwise in the course of 1 h to the refluxing solution and refluxing was continued for another 1 h. Chemical structure of TTHMP is shown in [Figure 1].
Radiolabeling of TTHMP with 175 YbCl 3
175YbCl 3 (2.85 mCi) dissolved in 0.1 mL of acidic medium (0.1 M HCl) was transferred to a 2 mL vial and the mixture was evaporated by slight warming under a nitrogen flow. Volumes of TTHMP solution (10 mg/mL) were added to activity containing vials. The mixtures were stirred at room temperature for up to 30-60 min. The active solution was checked for radiochemical purity three times for every 2 h by instant thin layer chromatography (ITLC). The pH of final solution was 7.5-8 and then filtered through a 0.22 μm millipore filter for sterilization.
Stability of 175 Yb-TTHMP complex
Frequent analyses have been performed using Whatman no. 3 chromatography paper in NH 4 OH:MeOH:H 2 O (1:10:20) system to determine the stability of the 175 Yb-TTHMP.
Serum stability studies
The stability of 175 Yb-TTHMP solution (200 μCi, 50 μl) was checked in presence of freshly prepared human serum (150 μl) at 37°C and was frequently tested for 2 days using above mentioned chromatography system.
Biodistribution studies in rats
In order to investigate biodistribution of 175 Yb-TTHMP, the data for biodistribution of free ytterbium cation in animals should be obtained. Biodistribution studies of 175 Yb cation and 175 Yb-TTHMP were carried out in rats weighing 200-250 g with three rats for each time point. The prepared formulation (150-200 μl, 100-150 μCi) were injected through the tail vein of the rats. The rats were sacrificed post-anesthesia at 2, 4, and 48 h and 4 and 8 days post injection. The tissues and organs were excised and the activity associated with each organ was measured in a NaI (Tl) scintillation counter. For each time interval three rats were used. Distribution of the activity in different organs was calculated as percentage of injected activity per gram of organ (ID/g%).
| Results and discussion|| |
Production of 175 Yb
Around 1.3-1.5 GBq/g (35-40 mCi/mg) of 175 Yb activity was obtained from natural Yb 2 O 3 target neutron bombarding. Irradiation of natural Yb 2 O 3 target also results in the formation of 169 Yb and 177 Lu as radionuclidic impurities. A typical gamma-ray spectrum of irradiated ytterbium is shown in [Figure 2]. The observed photo peaks correspond to the photo peaks of 175 Yb (113, 286, and 396 keV), 169 Yb (63, 110, 130, 177,198, 261, and 307 keV), and 177 Lu (208 and 112 keV).
Labeling optimization studies
In order to obtain the highest labeling yield, a quantitative study was performed using amount of 175 YbCl 3 with different molar ratio of TTHMP at room temperature (25°C). The results are shown in [Table 1].
Stability of 175 Yb-TTHMP in final formulation
The stability of the 175 Yb-TTHMP complex prepared under optimized reaction conditions was studied and it was observed that the complex has excellent stability at room temperature. The complex remained stable to the extent of 98% up to 8 days. The 175 Yb 3+ remained at the origin (R f = 0.0-0.1) and the 175 Yb-TTHMP complex migrates with the solvent to higher Rf (R f = 0.8).
The tissue distribution of 175 YbCl3 and 175 Yb-TTHMP determined in rats over 8 days is shown in [Figure 3] and [Figure 4], respectively. Specific activity of different organs was calculated as the percentage of injected dose per gram using NaI (Tl) detector. It can be seen from [Figure 3] accumulation of free Yb 3+ cation in the vital organs, that is, kidney, liver, lung, spleen, and heart are appreciable. [Figure 4] demonstrates favorable features of 175 Yb-TTHMP; such as, significant bone uptake-retention and rapid blood clearance.
|Figure 4: Percentage of injected dose per gram of 175Yb-triethylenetetramine hexamethylene phosphonic acid (TTHMP) in rats|
Click here to view
For the better comparison of two sample's behavior, vital organ uptake for free Yb-175 and 175 Yb-TTHMP are described. [Figure 5] demonstrates the blood accumulation from 2 h to 8 days. Because of the intravenous injection of solutions, accumulation of activities in blood is in the highest value at first 2 h and then 175 YbCl3 and 175 Yb-TTHMP are washed out from the circulation after 2 h, although the mechanisms of washout from blood are different.
|Figure 5: Comparative blood activity for 175Yb-TTHMP and 175YbCl3 in rats|
Click here to view
[Figure 6] demonstrates the bone accumulation from 2 h to 8 days. 175 Yb-TTHMP complex was rapidly taken up in the bone in 4 h after injection (ID/g% = 2.29) and remained almost constant up to 8 days (ID/g% = 2.85). Instead, uptake of the free Yb-175 increased slightly, but never exceeded 2%.
|Figure 6: Comparative bone activity for 175Yb-TTHMP and 175YbCl3 in rats|
Click here to view
In the case of the kidney, 175 Yb-TTHMP is rapidly taken up in bone and the trapping continues and almost no blood circulation is observed. The concentration of 175 Yb-TTHMP in kidney decreased from (ID/g% = 0.18) in 2 h to (ID/g% = 0.12) in 4 h and after 8 days it was negligible. But free 175 Yb as a water-soluble cation is washed out through kidney in 8 days [Figure 7].
|Figure 7: Comparative kidney activity for 175Yb-TTHMP and 175YbCl3 in rats|
Click here to view
Yb 3+ cation being transferred by serum metalloproteinase accumulates in liver and is excreted through hepatobiliary excretion route, leading to reduction in liver accumulation, while 175 Yb-TTHMP has almost no liver accumulation. This is a major advantage as a therapeutic radiopharmaceutical due to the possibility of increasing the maximum inject able dose [Figure 8].
|Figure 8: Comparative liver activity for 175Yb-TTHMP and 175YbCl3 in rats|
Click here to view
| Conclusion|| |
From the animal tests and quality control data results, 175 Yb-TTHMP shows suitable features to be used as alternative radiopharmaceutical for bone pain palliation. It was prepared and quality control was carried out in optimized conditions. Labeling and quality control took 1 h, radiochemical purity was higher than 95%, and radionuclidic purity was acceptable. The radiolabeled complex was stable in human serum for least 2 days. The biodistribution data on normal rats showed at least 70% accumulation of 175 Yb-TTHMP is in the bone tissues. Although it is not available in high specific activities, the uni-elemental abundance makes it an accessible and inexpensive radionuclide; and the obtained specific activity is enough for radiolabeling of small molecules at radiopharmaceutical grades. Therefore, in this situation and considering all of the excellent features of 175 Yb-TTHMP, this radiopharmaceutical can be used for effective management of bone pain palliation of skeletal metastases.
The institutional and international guide for the care and use of laboratory animals was followed. See the experimental part for details.
| References|| |
|1.||Yan M, Song S, Jiang Z. The clinical course of bone metastases of breast cancer. Chinese J Bone Tumor Bone Dis 2003;4:11. |
|2.||Ripamonti C, Dickerson ED. Strategies for the treatment of cancer pain in the new millennium. Drugs 2001;61:955-77. |
|3.||Serafini AN. Therapy of metastatic bone pain. J Nucl Med 2001;42:895-906. |
|4.||Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A, et al., European Association of Nuclear Medicine (EANM). EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 2008;35:1934-40. |
|5.||Volkert WA, Hoffman TJ. Therapeutic radiopharmaceuticals. Chem Rev 1999;99:2269-92. |
|6.||Hillegonds DJ, Franklin S, Shelton DK, Vijayakumar S, Vijayakumar V. The management of painful bone metastases with an emphasis on radionuclide therapy. J Natl Med Assoc 2007;99:785-94. |
|7.||Vimalnath KV, Shetty P, Chakraborty S, Das T, Chirayil V, Sarma HD, et al. Practicality of production of 32 P by direct neutron activation for its utilization in bone pain palliation as Na 3 [ 32 P] PO 4 . Cancer Biother Radiopharm 2013;28:423-8. |
|8.||Singh A, Holmes RA, Farhangi M, Volkert WA, Williams A, Stringham LM, et al. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med 1989;30:1814-8. |
|9.||Chakraborty S, Das T, Sarma HD, Venkatesh M, Banerjee S. Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis. Appl Radiat Isot 2008;66:1196-205. |
|10.||Kubota K, Yokoyama J, Yamaguchi K, Ono S, Qureshy A, Itoh M, et al. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: Comparison with MRI/CT. Eur J Nucl Med Mol Imaging 2004;31:590-5. |
|11.||Mathew B, Chakraborty S, Das T, Sarma HD, Banerjee S, Samuel G, et al. 175 Yb labeled polyaminophosphonates as potential agents for bone pain palliation. Appl Radiat Isot 2004;60:635-42. |
|12.||Srivastava SC. Treatment of bone and joint pain with electron emitting radiopharmaceuticals. Indian J Nucl Med 2004;19:89-97. |
|13.||Yousefnia H, Jalilian AR, Zolghadri S, Ghannadi-Maragheh M. Production, quality control, biodistribution assessment and preliminary dose evaluation of 177Lu-PDTMP as a possible bone palliaStive agent. Nucl Med Commun 2014;35:99-107. |
|14.||Bahrami-Samani A, Anvari A, Jalilian AR, Shirvani-Arani S, Yousefnia H, Aghamiri MR, et al. Production, quality control and pharmacokinetic studies of 177Lu-EDTMP for human bone pain palliation therapy trials. Iran J Pharm Res 2012;11:137-44. |
|15.||Pandit-Taskar N, Divgi CR. Targeted therapy for bone metastasis. In: Nuclear Oncology. Springer; 2013 . p.715-28. |
|16.||File END, Part B, Version V. National Nuclear Data Center. Brookhaven National Laboratory; 1990. |
|17.||Firestone RB, Chu S, Baglin CM. of the Table of Isotopes: 1998 Update; 1997. |
|18.||Naseri Z, Jalilian AR, Nemati Kharat A, Bahrami-Samani A, Ghannadi-Maragheh M. Production, quality control and biological evaluation of 153Sm-TTHMP as a possible bone palliation agent. Iran J Nucl Med 2012;19:60-8. |
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8]